Science & Innovation

Our research explores how bioactive compounds can support the body’s own protective and adaptive responses, from vascular protection and tissue repair to the modulation of pain signalling.

BBT-001 is a next-generation analogue of VCE-004.8 (Etrinabdione), a drug candidate that has reached Phase II clinical development in other vascular and fibrotic indications. Both compounds were co-designed by Professor Eduardo Muñoz Blanco, drawing on research into the mechanisms of vascular protection, angiogenesis, and tissue repair.

BBT-001 belongs to a family of analogues covered by a published patent application (PCT/EP2025/053266) developed at the University of Córdoba and the Maimonides Biomedical Research Institute of Córdoba (IMIBIC). BBT holds an exclusive license to the composition-of-matter patent application covering this family, providing a strong intellectual property foundation for its development.